Previous close | 214.55 |
Open | 212.30 |
Bid | 211.20 x N/A |
Ask | 222.00 x N/A |
Day's range | 212.30 - 218.40 |
52-week range | 212.30 - 298.40 |
Volume | |
Avg. volume | 916,406 |
Market cap | 183.8B |
Beta (5Y monthly) | 0.18 |
PE ratio (TTM) | 16.66 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 9.50 (3.99%) |
Ex-dividend date | 16 Mar 2023 |
1y target est | N/A |
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Q1 2024 Sarepta Therapeutics Inc Earnings Call
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.